Sabrina Paganoni

Credentials: · · · · ·

History

An Intermediate-Size Expanded Access Protocol (EAP) for NUZ-001 in People with Amyotrophic Lateral Sclerosis (NUZ-001 EAP)
National Institute of Neurological Disorders and Stroke · U01
Contact PI · $8.3M · Massachusetts General Hospital
2026–2030
Access for All in ALS (ALL ALS) East Clinical Coordinating Center
National Institute of Neurological Disorders and Stroke · OT2
PI · $71.5M · Massachusetts General Hospital
2023–2028
An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with Pridopidine
National Institute of Neurological Disorders and Stroke · U01
Contact PI · $29.6M · Massachusetts General Hospital
2023–2027
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis
National Institute of Neurological Disorders and Stroke · U01
PI · $33M · Massachusetts General Hospital
2023–2027

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
Principal investigator · Terminated · Phase 2
Alector Inc.
2021–2022
Open Label Extension Study of AMX0035 in Patients With ALS
Principal investigator · Completed · Phase 2
Amylyx Pharmaceuticals Inc.
2018–2021
Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)
Principal investigator · Completed · Phase 2
Massachusetts General Hospital
2017–2020
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Principal investigator · Completed · Phase 2
Amylyx Pharmaceuticals Inc.
2017–2019